Alnylam Pharmaceuticals (ALNY) Long-Term Deferred Tax (2009 - 2026)

Alnylam Pharmaceuticals has reported Long-Term Deferred Tax for 8 years, with the latest figure at $117.0 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Deferred Tax rose 9.08% year-over-year to $117.0 million; the trailing twelve-month figure through Mar 2026 stood at $117.0 million (up 9.08% YoY), and the FY2025 full-year result was $126.0 million, up 7.8% from the prior year.
• Long-Term Deferred Tax for Q1 2026 stood at $117.0 million, down from $126.0 million in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $126.0 million in Q4 2025, with the low at $10.1 million in Q4 2023.
• Historically, Long-Term Deferred Tax has averaged $97.1 million across 4 years, with a median of $107.2 million in 2025.
• Annual changes were most pronounced in 2024 — Long-Term Deferred Tax jumped 1056.94% — and 2025, when it grew 7.8%.
• Alnylam Pharmaceuticals' Long-Term Deferred Tax stood at $10.1 million in 2023, then jumped by 1056.94% to $116.9 million in 2024, then rose by 7.8% to $126.0 million in 2025, then fell by 7.16% to $117.0 million in 2026.
• The last three Long-Term Deferred Tax figures came in at $117.0 million (Q1 2026), $126.0 million (Q4 2025), and $98.6 million (Q3 2025), per Business Quant data.